179 related articles for article (PubMed ID: 37624080)
1. The Value of Pharmacogenomics for White and Indigenous Americans after Kidney Transplantation.
Brady A; Misra S; Abdelmalek M; Kekic A; Kunze K; Lim E; Jakob N; Mour G; Keddis MT
Pharmacy (Basel); 2023 Aug; 11(4):. PubMed ID: 37624080
[TBL] [Abstract][Full Text] [Related]
2. Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery.
Peterson PE; Nicholson WT; Moyer AM; Arendt CJ; Smischney NJ; Seelhammer TG; Krecke CA; Haney RM; Yaw EJ; Chlan LL
J Intensive Care Med; 2021 Nov; 36(11):1281-1285. PubMed ID: 32734840
[TBL] [Abstract][Full Text] [Related]
3. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
4. Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
Chambal M; Forsthoffer C; Egnaczyk A; Seitz M; Grande K; Ashcraft K; Wick JA; Blaxall BC
J Am Pharm Assoc (2003); 2023; 63(3):939-945. PubMed ID: 37024375
[TBL] [Abstract][Full Text] [Related]
5. Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report.
Del Toro-Pagán NM; Matos A; Thacker D; Turgeon J; Amin NS; Michaud V
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577878
[TBL] [Abstract][Full Text] [Related]
6. The pharmacogenomic landscape of an Indigenous Australian population.
Samarasinghe SR; Hoy W; Jadhao S; McMorran BJ; Guchelaar HJ; Nagaraj SH
Front Pharmacol; 2023; 14():1180640. PubMed ID: 37284308
[No Abstract] [Full Text] [Related]
7. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
[TBL] [Abstract][Full Text] [Related]
9. Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.
Matey ET; Ragan AK; Oyen LJ; Vitek CR; Aoudia SL; Ragab AK; Fee-Schroeder KC; Black JL; Moyer AM; Nicholson WT; Shrestha S; McAllister TM; Sinnwell JP; Faubion SS; Lazaridis KN
Pharmacogenomics J; 2022 Feb; 22(1):69-74. PubMed ID: 34671112
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
[TBL] [Abstract][Full Text] [Related]
11. Use of drugs with pharmacogenomics (PGx)-based dosing guidelines in a Danish cohort of persons with chronic kidney disease, both on dialysis and not on dialysis: Perspectives for prescribing optimization.
Westergaard N; Baltzer Houlind M; Christrup LL; Juul-Larsen HG; Strandhave C; Olesen AE
Basic Clin Pharmacol Toxicol; 2024 Apr; 134(4):531-542. PubMed ID: 38308569
[TBL] [Abstract][Full Text] [Related]
12. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
[TBL] [Abstract][Full Text] [Related]
13. Fetal pharmacogenomics: A promising addition to complex neonatal care.
Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
[TBL] [Abstract][Full Text] [Related]
14. Potentially actionable pharmacogenetic variants and symptom control medications in oncology.
Patel JN; Boselli D; Jandrisevits EJ; Hamadeh IS; Salem A; Meadors P; Walsh D
Support Care Cancer; 2021 Oct; 29(10):5927-5934. PubMed ID: 33758969
[TBL] [Abstract][Full Text] [Related]
15. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence.
Schuh MJ; Crosby S
Innov Pharm; 2020; 11(2):. PubMed ID: 34007616
[TBL] [Abstract][Full Text] [Related]
17. Applications for pharmacogenomics in pharmacy practice: A scoping review.
Hayashi M; Hamdy DA; Mahmoud SH
Res Social Adm Pharm; 2022 Jul; 18(7):3094-3118. PubMed ID: 34474980
[TBL] [Abstract][Full Text] [Related]
18. Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans.
Krulikas L; Bates J; Chanfreau C; Coleman H; Dalton S; Voora D
Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38775021
[TBL] [Abstract][Full Text] [Related]
19. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
[TBL] [Abstract][Full Text] [Related]
20. Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug-Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients.
Westergaard N; Søgaard Nielsen R; Jørgensen S; Vermehren C
J Pers Med; 2020 Jan; 10(1):. PubMed ID: 31963319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
